<?xml version='1.0' encoding='utf-8'?>
<document id="10870985"><sentence text="Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4."><entity charOffset="42-51" id="DDI-PubMed.10870985.s1.e0" text="triazolam" /><entity charOffset="56-68" id="DDI-PubMed.10870985.s1.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10870985.s1.e0" e2="DDI-PubMed.10870985.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10870985.s1.e0" e2="DDI-PubMed.10870985.s1.e1" /></sentence><sentence text="To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC)"><entity charOffset="58-67" id="DDI-PubMed.10870985.s2.e0" text="triazolam" /><entity charOffset="72-84" id="DDI-PubMed.10870985.s2.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10870985.s2.e0" e2="DDI-PubMed.10870985.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10870985.s2.e0" e2="DDI-PubMed.10870985.s2.e1" /></sentence><sentence text="" /><sentence text="HLM or REC was preincubated with erythromycin in the presence of NADPH and then triazolam was added"><entity charOffset="33-45" id="DDI-PubMed.10870985.s4.e0" text="erythromycin" /><entity charOffset="65-70" id="DDI-PubMed.10870985.s4.e1" text="NADPH" /><entity charOffset="80-89" id="DDI-PubMed.10870985.s4.e2" text="triazolam" /><pair ddi="false" e1="DDI-PubMed.10870985.s4.e0" e2="DDI-PubMed.10870985.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10870985.s4.e0" e2="DDI-PubMed.10870985.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10870985.s4.e0" e2="DDI-PubMed.10870985.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10870985.s4.e1" e2="DDI-PubMed.10870985.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10870985.s4.e1" e2="DDI-PubMed.10870985.s4.e2" /></sentence><sentence text=" alpha- and 4-hydroxy (OH) triazolam were quantified after a 3 min incubation and the kinetic parameters for enzyme inactivation (k(inact) and K('app)) were obtained" /><sentence text=" Drug-drug interaction in vivo was predicted based on a physiologically-based pharmacokinetic (PBPK) model, using triazolam and erythromycin pharmacokinetic parameters obtained from the literature and kinetic parameters for the enzyme inactivation obtained in the in vitro studies"><entity charOffset="114-123" id="DDI-PubMed.10870985.s6.e0" text="triazolam" /><entity charOffset="128-140" id="DDI-PubMed.10870985.s6.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10870985.s6.e0" e2="DDI-PubMed.10870985.s6.e0" /><pair ddi="false" e1="DDI-PubMed.10870985.s6.e0" e2="DDI-PubMed.10870985.s6.e1" /></sentence><sentence text="" /><sentence text="Whichever enzyme was used, triazolam metabolism was not inhibited without preincubation, even if the erythromycin concentration was increased"><entity charOffset="27-36" id="DDI-PubMed.10870985.s8.e0" text="triazolam" /><entity charOffset="101-113" id="DDI-PubMed.10870985.s8.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10870985.s8.e0" e2="DDI-PubMed.10870985.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10870985.s8.e0" e2="DDI-PubMed.10870985.s8.e1" /></sentence><sentence text=" The degree of inhibition depended on preincubation time and erythromycin concentration"><entity charOffset="61-73" id="DDI-PubMed.10870985.s9.e0" text="erythromycin" /></sentence><sentence text=" The values obtained for k(inact) and K('app) were 0" /><sentence text="062 min(-1) and 15" /><sentence text="9 microM (alpha-OH, HLM), 0"><entity charOffset="20-23" id="DDI-PubMed.10870985.s12.e0" text="HLM" /></sentence><sentence text="055 min(-1) and 17" /><sentence text="4 microM (4-OH, HLM), 0"><entity charOffset="16-19" id="DDI-PubMed.10870985.s14.e0" text="HLM" /></sentence><sentence text="173 min(-1) and 19" /><sentence text="1 microM (alpha-OH, REC), and 0" /><sentence text="097 min(-1) and 18" /><sentence text="9 microM (4-OH, REC)" /><sentence text=" Based on the kinetic parameters obtained using HLM and REC, the AUCpo of triazolam was predicted to increase 2"><entity charOffset="74-83" id="DDI-PubMed.10870985.s19.e0" text="triazolam" /><entity charOffset="48-56" id="DDI-PubMed.10870985.s19.e1" text="HLM" /><pair ddi="false" e1="DDI-PubMed.10870985.s19.e1" e2="DDI-PubMed.10870985.s19.e1" /><pair ddi="false" e1="DDI-PubMed.10870985.s19.e1" e2="DDI-PubMed.10870985.s19.e0" /></sentence><sentence text="0- and 2" /><sentence text="6-fold, respectively, following oral administration of erythromycin (333 mg t"><entity charOffset="55-67" id="DDI-PubMed.10870985.s21.e0" text="erythromycin" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=" for 3 days), which agreed well with the reported data" /><sentence text="" /><sentence text="In vivo interaction between triazolam and erythromycin was successfully predicted from in vitro data based on a PBPK model involving a mechanism-based inhibition of CYP3A4"><entity charOffset="28-37" id="DDI-PubMed.10870985.s26.e0" text="triazolam" /><entity charOffset="42-54" id="DDI-PubMed.10870985.s26.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.10870985.s26.e0" e2="DDI-PubMed.10870985.s26.e0" /><pair ddi="false" e1="DDI-PubMed.10870985.s26.e0" e2="DDI-PubMed.10870985.s26.e1" /></sentence><sentence text="" /></document>